Bioxytran, Inc. · OTC:BIXT
Bioxytran — Investor Presentation (December 2019)
32 slides from Bioxytran's investor presentation, Dec 11, 2019
Slide 1: David Platt, CEO
DAVID PLATT, CEO david.platt@bioxytraninc.com (617)-510-2539
Slide 2: Forward Looking Statement
Forward Looking Statement This report contains forward-looking statements concerning, among other things, possible applications for marketing approval and other regulatory matters, clinical trials, plans for the development of BioXyTran and business strategies. These forward-looking statements are i
Slide 3: Mission Statement
Mission Statement BioxyTran’s mission is to develop effective drug treatments for hypoxia (oxygen deficiency) which delivers oxygen to tissues with the potential to improve a myriad of medical conditions 3
Slide 4: Definition of Hypoxia
Definition of Hypoxia ® hy-pox-i-a /hi' pakséo/ noun MEDICINE deficiency in the amount of oxygen reaching the tissues. + oxygen deficiency in a biotic environment. “aquatic hypoxia" Bio.XyTran..
Slide 5: How Important is Oxygen?
How Important is Oxygen? How long can you hold your breath? Average Healthy Person can hold their breath about 2 minutes. Free Divers can hold their breath 3 – 5 minutes but can go down 100 meters 5
Slide 6: Survival Pyramid
Survival Pyramid What We Can’t Live Without 4-6 Minutes without oxygen 3 Days without water 21 Days without food 6
Slide 7: Hypoxia Implicated in Many Medical Conditions
Hypoxia Implicated in Many Medical Conditions - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587513/ - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356629/ - https://www.nature.com/articles/s12276-019-0235-1 - https://www.intechopen.com/books/hypoxia-and-human-diseases - https://www.intechopen.com
Slide 8: Cure for Hypoxia = Oxygen
Cure for Hypoxia = OXYGEN https://www.nobelprize.org/prizes/medicine/2019/press-release/ Nobel Prize Laureates 8
Slide 9: Hypoxia Science Research Won the Nobel Prize in 2019
Hypoxia Science Research Won the Nobel Prize in 2019 BIOXYTRAN… World Leader in the Field of Hypoxia ❑ BioxyTran has the only FDA approved device to measure tissue oxygenation ❑ Its MDX Viewer can quantify hypoxia (measuring the efficacy of treatments) ❑ BioxyTran is developing a molecule (BXT-25) t
Slide 10: BioxyTran Is Developing an Oxygen Transport Molecule BXT-25
BioxyTran Is Developing an Oxygen Transport Molecule BXT-25 Universal Challenge: Delivering oxygen to ischemic tissues and measuring the effect of increased oxygen levels Solution: Separating HEME from GLOBIN - Create molecule 5,000 times smaller than a red blood cell - Eliminate nitric oxygen scave
Slide 11: BioxyTran Combines Heme with a Co-Polymer
Expected Safety Profile of the Drug BXT-25 BioxyTran Combines Heme with a Co-Polymer Heme: An FDA approved material Co-polymer - FDA Approved Sugar that identifies and delivers oxygen + Stabilized Heme in Blood that eliminates Nitric Oxide Scavenging similar to red blood cells https://www.vox.com/fu
Slide 12: FDA Approved MDX Viewer Measures Hypoxia
FDA Approved MDX Viewer Measures Hypoxia Tool for Facilitating Drug Approval Approved Device Status Facilitates Defining Endpoint Potential Endpoints ❑ Tissue Metabolic Score FDA Approval Data ❑ Brain Metabolic Score https://www.accessdata.fda.gov/cdrh_docs/pdf6/K062977.pdf 12
Slide 13: Elements of a Blockbuster Drug
Elements of a Blockbuster Drug -Generate over $1.0 billion in annual revenue Blockbuster Drug List Lipitor, Epogen, Viagra, Taxol -Treat chronic diseases spanning many years Keytruda, Revlimid, Humira BXT-25? -Nominal side effects -Platform technology -Strong Intellectual property position 13
Slide 14: Bioxytran Following Celgene's Example
Bioxytran Following Celgene’s Example Celgene repurposed thalidomide which created a $74 billion purchase by Bristol Myers Squibb in 2019 Two years after approval in 2005, Revlimid reached -First approval in 1957 as a sedative – sleeping pill blockbuster status. -Few year later marketed as anti-naus
Slide 15: Upgrading Hemopure with New Chemistry
Bioxytran May Create Significant Value by Upgrading Hemopure with New Chemistry Hemopure Regulatory South Africa: 2001 Approval Dates in Russia and Approval History: Russia: 2012 South Africa: a list of other United States: Veterinary use only oxygen transport drug names http://jpet.aspetjournals.or
Slide 16: Hemopure Research Supports Bioxytran's Value
Hemopure Research Supports Bioxytran’s Value BXT-25 will be designed to; • Deliver optimum oxygen type to tissues • Increase measurable oxygen tissue levels • Restore organ functionality • Mitigate Hemopure’s side effects (nitric oxygen scavenging) 16
Slide 17: BXT-25 Will Optimize the Efficacy of Prior Technology
BXT-25 Will Optimize the Efficacy of Prior Technology 17
Slide 18: Strategy for Successful Commercialization of BXT-25
Strategy for Successful Commercialization of BXT-25 • Pursue functional claim of tissue oxygenation • Finalize development of MDX Viewer LICENSING DEAL • Prioritize stroke application in near term • Explore a myriad of other applications/treatments • Build core team to scale future growth • Enhance
Slide 19: BioxyTran Will Pursue a Functional vs. a Medical Claim
BioxyTran Will Pursue a Functional vs. a Medical Claim Most Drug Development Companies Pursue Medical Claims Example: Medical Claim (disease): The applicant claims the drug is for the treatment of ischemic stroke. The clinical endpoint for stroke is based on subjective cognitive tests. Functional Cl
Slide 20: Big Pharma Licensing Targets for BXT-25
Big Pharma Licensing Targets for BXT-25 Oncology Respiratory Neuroscience Hematology Immunology Inflammation Cardiovascular Stroke THERAPEUTIC AREAS FOR BXT-25 Johnson & Johnson – Oncology, Neuroscience, Immunology, Cardiovascular, Vaccines, HIV Roche Holdings – Oncology, Neuroscience, Immunology, H
Slide 21: Licensing Represents A Significant Opportunity
Licensing Represents A Significant Opportunity The US market potential for BXT-25 is estimated at $10 billion ▪ Cerebrovascular Accidents ▪ Anemia Treatment ▪ Traumatic Brain Injury (TBI) ▪ Cancer ▪ Anti-Necrosis ▪ Human Organ Transplants 21
Slide 22: Inadequate Treatment Options
Inadequate Treatment Options STEP 1 – Determination of Ischemic or Hemorrhagic Stroke (Imaging) STEP 2 – Tissue Plasminogen Activator (tPA) for Ischemic Stroke or Surgery – [Clipping Artery, Insert Coiling to Force Clotting] for Hemorrhagic NO TREATMENT CAN BE GIVEN UNTIL DIAGNOSIS IS COMPLETED 13%
Slide 23: Ideal Stroke Treatment
Ideal Stroke Treatment EVERY MINUTE COUNTS! ULTIMATE TREATMENT CHARACTERISTICS - Restore Oxygen to the Brain - Efficacy for Ischemic and Hemorrhagic Strokes - No Side Effects - Easy to Administer Treatment for First Responders THE CONCEPT BEHIND BXT-25 EXTEND THE “GOLDEN HOUR” TO TREAT STROKE VICTIM
Slide 24: The Brain Stroke Epidemic
The Brain Stroke Epidemic REGION STROKES POPULATION SURVIVORS DIRECT COST INDIRECT COST (MILLIONS) (MILLIONS) (MILLIONS) (BILLIONS) (BILLIONS) US 0.8 321 5.8 $44 $22 EU (+GB) 1.1 743 3.4 $28 $16 CN 2.5 1,371 7.5 estimated $74 World 17.0 7,500 33.0 estimated $184 24
Slide 25: BXT-25 Is Designed with Characteristics for Stroke Treatment
BXT-25 Is Designed with Characteristics for Stroke Treatment - Restores oxygen to the brain - Creates efficacy for both ischemic and hemorrhagic strokes - Results in no known side effects - Delivers viable treatment for first responders - Enables immediate treatment prior to diagnostic imaging 25
Slide 26: Hyperbaric Chamber Obsolescence
Hyperbaric Chamber Obsolescence Hyperbaric Chamber Indications Advantages – Easier administration 1 shot could equal nine 1-hour sessions in -Decompression Sickness hyperbaric chamber -Wound Healing -Burn victims - Major expanse in clinical research possible -Infections - Only 1 hour of hyperbaric c
Slide 27: Licensing Zone
Licensing Zone • Complete safety studies in healthy human patients • Target coma patients for initial studies • Create credibility of third vital sign with influencers • Raise $10 million in equity related financing • Identify and approach key target licensees • Attract research coverage and institu
Slide 28: Bioxytran Has a Clear Plan to Achieve FDA Approval
Bioxytran Has a Clear Plan to Achieve FDA Approval 1. CMC Production 5. CMC Production 6. Phase I(a) 8. Phase III • Manufacture (USA) • Manufacture (USA) • Healthy Volunteers (40) • Stroke Patients (300) • Human Heme • Human Heme • Dose Limiting Toxicity • National Institute of • GLP • GMP • Immunol
Slide 29: Leadership
Leadership INDEPENDENT BOARD OF MEDICAL ADVISORY BOARD MANAGEMENT DIRECTORS Alan Hoberman, PhD Avraham Mayevsky, PhD David Platt, Ph.D/CEO Worldwide authority in the field of minimal invasive Executive Director at Charles River Laboratories Ph.D in Chemical Engineering, Hebrew University of monitori
Slide 30: Use of Proceeds
Use of Proceeds Event FUNDING TIMELINE PATIENTS Manufacturing CMC $400K 4 mo. Preclinical (2 Species – Rats & Dogs) $600K 3 mo. Phase 1 (BXT-25) $400K 2 mo. 30 Phase 2 $2.0 mil 6 mo. 60 SG&A Expense $3.4 mil MDX Licensing Deal $3.2 mil Total $10 Million 30
Slide 31: Effective S-1
Effective S-1 Proposed Maximum Amount to be Offering Title of Each Class of Security Being Registered Registered Price Common Stock, $0.001 par value 10,000,000 $ 1.00 Common Stock, $0.001 par value (3) 3,285,821 Common Stock Underlying Warrants (4) 208,333 Total 13,494,154 (1) Estimated solely for
Slide 32: BioXyTran, Inc. David Platt, CEO
BioXyTran, Inc. 233 Needham St., Suite 300 Newton MA, 02464 (617)-454-1199 www.bioxytraninc.com David Platt, CEO david.platt@bioxytraninc.com (617)-510-2539